Two single nucleotide polymorphisms in ALOX15 are associated with risk of coronary artery disease in a Chinese Han population

Arachidonate 12/15-lipoxygenase (12/15-LOX) has been implicated in the pathogenesis of atherosclerosis, but with contradicting results. The aim of this study was to investigate the association of two polymorphisms in ALOX15 and the risk of coronary artery disease (CAD) in a Chinese Han population. A total of 519 unrelated CAD patients and 608 unrelated control subjects of the Chinese Han population were recruited in the case-control study. Two tagSNPs, rs7217186:T>C and rs2619112:G>A, were selected and genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The carriers of the C allele (the CC homozygote and the CT heterozygote) of rs7217186:T>C and the carriers of the A allele (the AA homozygote and the GA heterozygote) of rs2619112:G>A displayed elevated odds ratios (ORs) for CAD compared with the TT homozygotes and GG homozygotes, respectively, after adjusting for other potential confounders including age, sex, body mass index, systolic blood pressure, diastolic blood pressure, glucose, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and smoking status (adjusted odds ratio [OR] = 3.2, 95% confidence interval [CI]: 1.335–7.665, P = 0.009 and adjusted OR = 3.5, 95% CI: 1.343–9.330, P = 0.011). In stratified analyses, after adjusting those aforementioned confounders, the CC and CT genotypes of rs7217186:T>C were associated with a greater risk of CAD in subjects <60 years (adjusted OR = 5.7, 95% CI: 1.557–21.097, P = 0.009) and in females (adjusted OR = 9.3, 95% CI: 1.048–82.213, P = 0.045). For rs2619112:G>A, subjects (<60 years) carrying the A allele had a greater risk of CAD than the GG homozygotes (adjusted OR = 4.9, 95% CI: 1.215–19.547, P = 0.025); the male carriers of A allele also had a greater risk (adjusted OR = 3.5, 95% CI: 1.136–11.006, P = 0.029). In summary, the present study shows that after adjustment for other confounding CAD factors, rs7217186:T>C and rs2619112:G>A of ALOX15 are associated with increased risk of CAD in this Chinese Han population.

[1]  S. Murota,et al.  Comparative effect of lipoxygenase products of arachidonic acid on rat aortic smooth muscle cell migration. , 1982, Atherosclerosis.

[2]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[4]  C. Glass,et al.  Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[6]  L. Chan,et al.  Transgenic rabbits with the integrated human 15‐lipoxygenase gene driven by a lysozyme promoter: macrophage‐specific expression and variable positional specificity of the transgenic enzyme , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  T. Nikkari,et al.  Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. , 1995, Circulation.

[8]  J. Cornhill,et al.  Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. , 1996, The Journal of clinical investigation.

[9]  J. Wölle,et al.  Transient overexpression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression. , 1996, Biochemical and biophysical research communications.

[10]  Jullia A. Rosdahl,et al.  Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells. , 1997, Hypertension.

[11]  D. Heydeck,et al.  In vivo action of 15-lipoxygenase in early stages of human atherogenesis. , 1997, The Journal of clinical investigation.

[12]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[13]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[14]  B. Thiele,et al.  The diversity of the lipoxygenase family , 1999, FEBS letters.

[15]  R. Natarajan,et al.  Evidence for 12-lipoxygenase induction in the vessel wall following balloon injury. , 1999, Cardiovascular research.

[16]  D. Steinberg,et al.  The oxidative modification hypothesis of atherogenesis: an overview. , 2000, Free radical biology & medicine.

[17]  J. Terao,et al.  Inhibitory Effect of Flavonoids on Low‐Density Lipoprotein Peroxidation Catalyzed by Mammalian 15‐Lipoxygenase , 2000, IUBMB life.

[18]  V. A. Folcik,et al.  Lipoxygenases and atherosclerosis: protection versus pathogenesis. , 2000, Free radical biology & medicine.

[19]  Lei Zhao,et al.  12/15-Lipoxygenase Gene Disruption Attenuates Atherogenesis in LDL Receptor–Deficient Mice , 2001, Circulation.

[20]  D. Rader,et al.  Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[21]  Daniel Steinberg,et al.  Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime , 2002, Nature Medicine.

[22]  C. Gerth,et al.  Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type 15-lipoxygenase and protects from aortic lipid deposition. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[23]  R. Natarajan,et al.  12/15-Lipoxygenase Activity Mediates Inflammatory Monocyte/Endothelial Interactions and Atherosclerosis in Vivo* , 2004, Journal of Biological Chemistry.

[24]  R. Natarajan,et al.  The Effects of Leukocyte-Type 12/15-Lipoxygenase on Id3-Mediated Vascular Smooth Muscle Cell Growth , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[25]  P. Puddu,et al.  Genes and atherosclerosis: at the origin of the predisposition , 2005, International journal of clinical practice.

[26]  M. Schwartz,et al.  12/15-Lipoxygenase Regulates Intercellular Adhesion Molecule-1 Expression and Monocyte Adhesion to Endothelium Through Activation of RhoA and Nuclear Factor-&kgr;B , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Jonas Wittwer,et al.  Functional polymorphism in ALOX15 results in increased allele‐specific transcription in macrophages through binding of the transcription factor SPI1 , 2006, Human mutation.

[28]  M. Hersberger,et al.  The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective , 2007, Clinical chemistry and laboratory medicine.

[29]  E. Goloni-Bertollo,et al.  Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population , 2008, Heart and Vessels.

[30]  T. Assimes,et al.  A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. , 2008, Atherosclerosis.

[31]  J. Krauze,et al.  Synergistic effects between 561A > C and 98G > T polymorphisms of E-selectin gene and hypercholesterolemia in determining the susceptibility to coronary artery disease , 2008, Heart and Vessels.

[32]  Lyle J. Palmer,et al.  15-Lipoxygenase gene variants are associated with carotid plaque but not carotid intima-media thickness , 2008, Human Genetics.

[33]  C. Serhan,et al.  Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  F. Kronenberg,et al.  No association of two functional polymorphisms in human ALOX15 with myocardial infarction. , 2009, Atherosclerosis.